TaiwanJ Pharmaceuticals Co., Ltd.

TPEX:6549 Stock Report

Market Cap: NT$746.7m

TaiwanJ Pharmaceuticals Valuation

Is 6549 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6549 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6549's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6549's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6549?

Key metric: As 6549 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 6549. This is calculated by dividing 6549's market cap by their current book value.
What is 6549's PB Ratio?
PB Ratio12.9x
BookNT$57.35m
Market CapNT$746.74m

Price to Book Ratio vs Peers

How does 6549's PB Ratio compare to its peers?

The above table shows the PB ratio for 6549 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.4x
7595 Pharmigene
2xn/aNT$767.1m
6652 Eusol BiotechLtd
2.7xn/aNT$1.0b
7561 Bioray Biotech
1.5xn/aNT$611.6m
4131 NeoCore Technology
3.7xn/aNT$1.1b
6549 TaiwanJ Pharmaceuticals
13xn/aNT$746.7m

Price-To-Book vs Peers: 6549 is expensive based on its Price-To-Book Ratio (13x) compared to the peer average (2.4x).

Price to Book Ratio vs Industry

How does 6549's PB Ratio compare vs other companies in the TW Biotechs Industry?

0 CompaniesPrice / BookEstimated GrowthMarket Cap
No more companies available in this PB range
6549 12.9xIndustry Avg. 3.8xNo. of Companies7PB02.44.87.29.612+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 6549 is expensive based on its Price-To-Book Ratio (13x) compared to the TW Biotechs industry average (3.8x).

Price to Book Ratio vs Fair Ratio

What is 6549's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6549 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio12.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 6549's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

YungShin Global Holding

NT$15.5b

Through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics in Taiwan, Mainland China, Japan, and the United States.

3705

NT$58.10

7D

8.6%

1Y

27.7%

RBC Bioscience

NT$258.9m

Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia.

6848

NT$19.95

7D

-0.7%

1Y

32.1%

Cenra

NT$6.0b

Engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals.

1701

NT$21.15

7D

0%

1Y

-8.8%